BSL3 Biomedicum Core Facility - our offer

BSL3 Biomedicum Core Facility serves a growing body of researchers at Karolinska Institutet working on risk-group 3 bacteria, parasites and viruses.

BSL3 Biomedicum Core Facility has two interconnected but separate barriers approved by the Swedish Work Environment Authority to handle the following risk-group 3 pathogens within its respective barriers.

Airborne suite

  • Mycobacterium tuberculosis
  • SARS-CoV-2
  • Monkeypox virus

Non-airborne suite

  • Chikungunya virus
  • Leishmania brasiliensis, L. donovani
  • HIV
  • Plasmodium falciparum


The facility supports various research activities integrated in its capabilities available also as a service to users. These capabilities include:

  • High throughput antiviral and antibiotic screening 
  • Aerobiology investigative techniques
  • Large-scale propagation and concentration of risk-group 3 pathogens
  • In vitro infections 
  • 10x Genomics single-cell RNA sequencing (in collaboration with the Eukaryotic Single Cell Genomics platform at SciLifeLab, Solna) 
  • Cell sorting and Flow cytometry (in collaboration with Biomedicum Flow Cytometry Core)
  • Various methods for pathogen inactivation and equipment decontamination, including hydrogen-peroxide vapor decontamination
  • Developing new methods in BSL3
  • Helping users with experiments 

Support, collaborations and other initiatives

BSL3 Biomedicum receives core-facility funding from Karolinska Institutet.

The facility collaborates with SciLifeLab platforms in Solna and is open to partnerships in academia, healthcare and the private sector. 

BSL3 Biomedicum  is leading a Pandemic Laboratory Preparedness initiative for Swedish BSL3 laboratories: Swedish BSL3 Network

BSL3 Biomedicum Core Facility - lab environment

Llab envorinment from BSL3 lab in Biomedicum
Image gallery